SAN.PA - Sanofi
| Previous Close | 65.87 |
| Open | 66.11 |
| Bid | 71.12 x 1000 |
| Ask | 71.74 x 44000 |
| Day's Range | 66.03 - 66.60 |
| 52 Week Range | 25.38 - 87.65 |
| Volume | 1,452,682 |
| Avg. Volume | 7,583 |
| Market Cap | 82.936B |
| Beta | 0.84 |
| PE Ratio (TTM) | 9.99 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.03 (4.59%) |
| Ex-Dividend Date | 2018-05-11 |
| 1y Target Est | N/A |
Reuters Videos•9 days agoSanofi in talks to sell generics arm for $2.4 bln
French healthcare group Sanofi is in exclusive talks to sell its Zentiva European generics drugs arm to private equity firm Advent International for 1.9 billion euros ($2.4 billion). Sonia Legg reports.
- Reuters•yesterday
Boehringer's operating income up 20.7 percent on Sanofi deal
Boehringer Ingelheim, Germany's second-largest drugmaker, posted a gain in operating income of 20.7 percent to 3.5 billion euros (3.06 billion pounds) last year, boosted by the purchase of Sanofi's (SASY.PA) veterinary medicine. The asset swap saw unlisted Boehringer take Sanofi's $13.5 billion animal health subsidiary, making it the world's second-largest player in the industry after Zoetis (ZTS.N). In return, Sanofi obtained the German company's consumer health care business unit, valued at nearly $8 billion, plus $5.5 billion in cash from Boehringer, which Boehringer at the time paid largely from existing liquidity on its balance sheet.
- Reuters•yesterday
Boehringer's operating income up 20.7 percent on Sanofi deal
Boehringer Ingelheim, Germany's second-largest drugmaker, posted a gain in operating income of 20.7 percent to 3.5 billion euros ($4.27 billion) last year, boosted by the purchase of Sanofi's veterinary medicine. The asset swap saw unlisted Boehringer take Sanofi's $13.5 billion animal health subsidiary, making it the world's second-largest player in the industry after Zoetis. In return, Sanofi obtained the German company's consumer health care business unit, valued at nearly $8 billion, plus $5.5 billion in cash from Boehringer, which Boehringer at the time paid largely from existing liquidity on its balance sheet.
- Reuters•2 days ago
UK bans Sanofi epilepsy drug without pregnancy prevention plan
A Sanofi (SASY.PA) drug for epilepsy and bipolar disorder linked to thousands of birth defects has been banned in Britain for use in women or girls of child-bearing age, unless they are on a special pregnancy prevention programme. The move follows a scandal over the lack of information given to patients about the risks associated with valproate, which was first approved in France in 1967 and remains a widely used treatment for epilepsy. It is sold by Sanofi under the brand Depakine for epilepsy and Depakote and Depamide for bipolar disorders.
- Simply Wall St.•2 days ago
Sanofi (EPA:SAN): Immense Growth Potential?
Sanofi’s (ENXTPA:SAN) latest earnings announcement in December 2017 showed that the business experienced a significant headwind with earnings declining by -13.74%. Today I want to provide a brief commentary onRead More...
- Motley Fool•6 days ago
Why Dicerna Rocketed Higher Today
Investors are happy the biotech ended a lawsuit hanging over its head.
- Reuters•7 days ago
WHO recommends testing before use of Sanofi's dengue vaccine
The World Health Organisation on Thursday said Sanofi's vaccine against dengue should only be used after testing individuals to assess whether they could have been exposed before to the infection. "We have now clear information that the vaccine needs to be dealt in a safer way by using it exclusively in people already infected," Alejandro Cravioto, Chair of the WHO's Strategic Advisory Group of Experts (SAGE) on Immunization, told journalists. After new analysis of data, Sanofi warned in November the vaccine could increase the risk of severe dengue in some cases in people who had not been previously exposed to the disease.
- Zacks•7 days ago
Sanofi to Divest European Generic Unit, Streamline Business
Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.
- Reuters•9 days ago
Sanofi's CFO Contamine to retire later this year
PARIS (Reuters) - Sanofi's (SASY.PA) executive vice president and chief financial officer, Jerome Contamine, plans to retire later this year, the French drugmaker said on Tuesday. In an emailed statement, ...
- Bloomberg•9 days ago
Sanofi Finance Chief to Leave After Almost a Decade at Drugmaker
Sanofi Chief Financial Officer Jerome Contamine is planning to step down from the French drugmaker later this year after almost a decade in the job.
- The Wall Street Journal•9 days ago
[$$] Advent in Exclusivity to Buy Czech Drugmaker Zentiva for €1.9 Billion
The firm has presented a €1.9 billion ($2.35 billion) binding offer for the drugmaker.
- Bloomberg•9 days ago
In Pharma, If You Can't Join Them, Beat Them
Advent is preparing to take on a drugmaker it tried and failed to buy.
- Reuters•9 days ago
Bank trio expected to lead financing on Zentiva sale
Goldman Sachs, JP Morgan and Morgan Stanley are expected to lead a debt financing totalling in excess of €1bn backing private equity firm Advent International’s acquisition of French healthcare group Sanofi’s (SASY.PA) European generics drugs arm Zentiva, banking sources said. Sanofi entered exclusive talks to sell Zentiva to Advent for €1.9bn, including equity and debt, the companies said on Tuesday.
- Reuters•9 days ago
Sanofi in talks to sell generics arm to Advent for $2.4 billion
French healthcare group Sanofi is in exclusive talks to sell its Zentiva European generics drugs arm to private equity firm Advent International for 1.9 billion euros ($2.4 billion), the companies said on Tuesday. Sanofi said the sale was expected to be completed before the end of the year, and Advent's offer was binding and fully financed. The 1.9 billion euros price is an enterprise value, including equity and debt.
- Reuters•9 days ago
Sanofi in talks to sell generics arm to Advent for $2.4 bln
French healthcare group Sanofi is in exclusive talks to sell its Zentiva European generics drugs arm to private equity firm Advent International for 1.9 billion euros ($2.4 billion), the companies said on Tuesday. Sanofi said the sale was expected to be completed before the end of the year, and Advent's offer was binding and fully financed. The 1.9 billion euros price is an enterprise value, including equity and debt.
- Financial Times•9 days ago
[$$] Advent in exclusive talks to buy Sanofi generics business
Private equity firm Advent has confirmed that it has entered into exclusive negotiations to buy Zentiva, Sanofi’s European generics business, for €1.91bn. A statement from the two firms on Tuesday said ...
- The Wall Street Journal•9 days ago
[$$] Sanofi in Talks With Advent to Sell Zentiva
Sanofi said it has entered exclusive talks to sell its European generic business Zentiva to Advent International for €1.92 billion.
- Bloomberg•9 days ago
Sanofi to Sell Generics for $2.4 Billion to Focus on Biotech
Sanofi plans to sell its European generic-drug unit to buyout firm Advent International Corp. for 1.9 billion euros ($2.4 billion) as part of a broader move by Chief Executive Officer Olivier Brandicourt ...
- The Wall Street Journal•10 days ago
[$$] Charterhouse Portfolio Company Closes Sanofi Deal
Cooper-Vemedia paid €158 million ($194.8 million) for 12 pharmaceutical brands.
- Reuters•10 days ago
France's Sanofi sells 12 brands to Charterhouse's Cooper-Vemedia
French healthcare and drugs group Sanofi (SASY.PA) has agreed to sell a portfolio of 12 pharmaceutical brands to Charterhouse Capital Partners' Cooper-Vemedia drugs manufacturing arm for 158 million euros (£136.6 million), the companies said on Monday. Sanofi said the sale formed part of its strategy to focus on its main businesses in areas such as allergy treatments and nutritional products, and to simplify its business portfolio. Private equity and investment firm Charterhouse Capital said the acquisition would help build up the healthcare portfolio of Cooper-Vemedia, which is a European drug manufacturer and distributor.
- Reuters•11 days ago
PRESS DIGEST- Financial Times - April 16
The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines * Barclays creates venture capital-style unit https://on.ft.com/2qCe467 ...
- Bloomberg•11 days ago
Advent Is Said to Near Deal to Acquire Sanofi Generics Unit
Advent International Corp. is close to acquiring Sanofi’s European generics division in a deal valued at about 2 billion euros ($2.5 billion) including debt, people with knowledge of the matter said.
- Financial Times•11 days ago
[$$] Advent nears deal to buy Sanofi generics business
Advent International, the US buyout group, is close to clinching a deal to buy the European generics business of Sanofi , according to two people familiar with the transaction. The news comes after the ...
- Financial Times•13 days ago
[$$] Advent leads race to buy Sanofi’s generics arm
Advent International has pulled ahead in the race to acquire the European generics unit of French pharmaceutical company Sanofi as it tries to fend off competition from both trade and financial buyers, ...
- Financial Times•13 days ago
[$$] Advent International closes in on deal for Sanofi’s generics unit
Advent International has pulled ahead in the race to acquire the European generics unit of French pharmaceutical company Sanofi , as it tries to fend off competition from both trade and financial buyers, ...
